
Biogen to acquire RayThera for up to $1B, boosting immunology pipeline with new drug candidates.
Biogen has agreed to acquire RayThera Inc. for up to $1 billion, including upfront and milestone payments. This acquisition adds multiple anti-inflammatory drug candidates to Biogen's immunology portfolio, with the lead asset expected to enter Phase ...

